SCHEMBL957262

SCHEMBL957262

CC(C)NCCCCOc1ccc(-c2ccc(C(=O)O)c(Cl)c2)cc1-c1ccc2c(c1)C(C)(C)CCC2(C)C

nearest known ligand 0.66

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
RARG P13631 17/20 0.66
RARB P10826 8/20 0.58
RARA P10276 8/20 0.58
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL955464 0.90 RARG (0.59) RARGRARBRARANPSR1KDM4E
SCHEMBL4655882 0.90 RARG (0.56) RARGRARBRARANPSR1KDM4E
SCHEMBL958732 0.90 RARG (0.58) RARGRARBRARAKDM4EALDH1A1
SCHEMBL959850 0.90 RARG (0.67) RARGRARBRARAKDM4EALDH1A1
SCHEMBL957391 0.88 RARG (0.56) RARGRARBRARANPSR1KDM4E
SCHEMBL955172 0.88 RARG (0.68) RARGRARBRARANPSR1RXRA
SCHEMBL956001 0.88 RARG (0.76) RARGRARBRARARXRA
SCHEMBL955370 0.87 RARG (0.75) RARGRARBRARARXRA
SCHEMBL4654752 0.85 RARG (0.61) RARGRARBRARANPSR1KDM4E
SCHEMBL956218 0.85 RARG (0.75) RARGRARBRARARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872026-B2 Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-18 US claimed
EP-1692093-B1 BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2008-11-19 EP claimed
US-20070021473-A1 Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-01-25 US claimed
US-7872026-B2 Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-18 US disclosed
EP-1692093-B1 BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2008-11-19 EP disclosed
US-20070021473-A1 Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-01-25 US disclosed
EP-1692093-A1 BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development, S.N.C. (FR) 2006-08-23 EP disclosed
WO-2005056516-A1 BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021473-A1 Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof RARA, RARB, RARG RARG 3/4885RARB 2/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.